Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Ultragenyx Pharma (RARE) Tops Q4 EPS by 3c, Revenues Beat
February 13, 2020 4:04 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.62), $0.03 better than the analyst estimate of ($1.65). Revenue for the quarter came in at $35.6 million versus the consensus estimate of $32.15 million.
In 2019 we created a substantial foundation based on the strong launch of Crysvita and the validation of our gene therapy platform across multiple clinical programs, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of... More
